Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Everplay shares surge on return to profit, outlook

(Sharecast News) - Shares in Everplay surged on Wednesday as the video game maker returned to profit and said current-year trading would be marginally ahead of expectations. Pre-tax profit came in at £25.3m for the year to December compared with a loss of £1.1m a year earlier. Revenue rose 5% to £166m, driven by an increase in first-party IP revenues, which contributed 37% to the overall figure.

Shares in the firm, which rebranded from its original Team17 name in January, were up 15% in early London trade.

"The group has made a good start to 2025, supported by the momentum from the festive season promotions. As a result, the board remains confident that the group can deliver an improved trading performance in 2025, marginally ahead of current market expectations, and remains well positioned for continued growth over the medium to long term," the company said.

Everplay is made up of three divisions; Astragon, which publishes working simulation games, StoryToys which develops and publishes educational entertainment apps for children and Team17 an independent games label.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.